John McConnell to Prostate
This is a "connection" page, showing publications John McConnell has written about Prostate.
Connection Strength
0.338
-
Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012 Dec; 62(6):953-61.
Score: 0.103
-
Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY, Rotonda J, Kusek JW, Nyberg LM. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008 Sep; 180(3):1030-2; discussion 1032-3.
Score: 0.079
-
Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006 Jan; 175(1):217-20; discussion 220-1.
Score: 0.066
-
Lin VK, Wang SY, Boetticher NC, Vazquez DV, Saboorian H, McConnell JD, Roehrborn CG. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate. 2005 May 15; 63(3):299-308.
Score: 0.063
-
Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003 Apr; 61(4):791-6.
Score: 0.014
-
Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002 Feb 01; 94(3):690-9.
Score: 0.013